|
|
||||||||


*
Dipartimento di Medicina Sperimentale e Clinica, Università di Catanzaro Magna Graecia, Catanzaro, Italy;
Department of Pediatric Gastroenterology, St. Bartholomews and Royal London School of Medicine and Dentistry, London, United Kingdom;
Cattedra di Gastroenterologia, Seconda Università di Napoli, Naples, Italy;
§
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Naples, Italy; and
¶
Università di Roma Tor Vergata, Rome, Italy
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In recent years considerable evidence has been accumulated to indicate that IL-8, the major human PMN chemoattractant, plays a major role in the Hp-associated acute inflammatory response (2, 3, 4). Both IL-8 mRNA and protein levels strictly correlate with Hp density (5, 6). In addition, IL-8 expression has been associated with significantly more severe infiltration of PMN, and down-regulation of mucosal IL-8 synthesis, induced by Hp eradication, is paralleled by a resolution of the PMN infiltration (7, 8). During Hp infection, epithelial cells are the major producers of IL-8, even if there is evidence that macrophage-like cells synthesize IL-8 (3). Although several studies have documented the ability of Hp to directly stimulate IL-8 synthesis, there is evidence that T cell-derived cytokines may modulate epithelial cell IL-8 gene expression (9).
IL-17 is a recently described cytokine encoded by a 155-aa open reading
frame that includes an N-terminal secretion signal sequence of 1923
residues (10). IL-17 is produced by activated
CD4+ T lymphocytes, mainly Th0 and Th1 cells
(11), and exhibits pleiotropic biological activities on
various cell types, including macrophages, fibroblasts, and endothelial
and epithelial cells (12). IL-17 has been found to
stimulate the synthesis of IL-1ß, IL-6, TNF-
,
PGE2, ICAM-1 and cyclo-oxygenase-2 (13, 14). Thus, IL-17 appears to provide a link between T cell
activation and inflammatory responses. Consistently, an enhanced
expression of IL-17 has been documented and implicated in the
pathogenesis of immune-mediated diseases, such as rheumatoid arthritis,
multiple sclerosis, and psoriasis (14). Moreover, IL-17
has the ability to stimulate IL-8 production in both epithelial cells
and macrophages (13, 15), raising the possibility that
this cytokine may play an important role in the recruitment of
inflammatory cells during bacteria infections.
Knowing that activation of CD4+ Th1 cells is a key feature of Hp infection (16, 17, 18), we explored the hypothesis that the locally induced IL-17 may be involved in the local inflammatory response to gastric Hp colonization. In this work we report for the first time that biologically active IL-17 production is increased in the mucosa of Hp-infected patients. In addition, we show that IL-17 is capable of stimulating IL-8 release by gastric epithelial cells and favoring PMN chemotaxis through an IL-8-dependent mechanism. These data suggest that IL-17 may play an important role in the maintenance of the mucosal inflammatory response during Hp infection.
| Materials and Methods |
|---|
|
|
|---|
Thirty-six patients (18 men and 18 women; age range, 1971 years; median, 39 years) who underwent esophagogastroduodenoscopy for dyspeptic symptoms were studied. Endoscopic findings were as follows: normal mucosa or mild gastric erythema, 26 patients; esophagitis, five patients; erosive duodenitis, two patients; duodenal ulcer, two patients; and erosive gastritis, one patient. Twenty-nine patients had evidence of Hp infection. Nine Hp-infected patients were re-endoscoped 1 mo after cessation of 1-wk treatment with lansoprazole (60 mg twice daily), tinidazole (500 mg twice daily), and clarithromycin (500 mg twice daily). Six of these nine patients were Hp eradicated. Seven of the 36 patients were Hp negative. Mucosal samples, with no evidence of macroscopic and histological lesions, were taken from these seven patients and considered as normal tissue. During endoscopy eight gastric biopsy specimens were taken: one from the antrum for urease quick test (Yamanouchi Pharma, Milan, Italy), four from the antrum and corpus for histological examination, and three from the antrum for cytokine measurement. All 36 patients were used as sources of tissue for Hp-positive and Hp-negative patients. Autologous PBMC were obtained from three Hp-infected and three uninfected patients. At this time a blood sample was drawn from each patient. No patient had previously undergone anti-Hp treatment or had received antibiotics within the previous 2 mo. Informed consent was obtained from all patients, and the protocol was approved by the local ethical committee.
Histological examination
Sections of biopsy specimens were embedded in paraffin and stained with hematoxylin and eosin to examine gastritis and with Giemsa to detect Hp. The degree and activity of gastritis and the density of Hp colonization, atrophy, and intestinal metaplasia were graded according to the Sydney system (19) on a four-point scale: 0, no; 1, mild; 2, moderate; and 3, severe changes.
Determination of Hp status
Patients were classified as Hp infected when the urease quick test result was positive and/or the organism was identified in the Giemsa-stained sections in the antral and/or corpus gastric samples. A [13C]urea breath test (Cortex, Milan, Italy) was also performed, and successful eradication of Hp was determined if all test results were negative.
Gastric lamina propria mononuclear cell (LPMC) and MKN 28 cell cultures
Gastric LPMC were isolated by the DTT-EDTA-collagenase sequence as previously described in detail (20). The resulting cell preparations contained <5% contaminating epithelial cells. The isolated cells were counted and checked for viability using 0.1% trypan blue (viability ranged from 9094%). Gastric LPMC were resuspended in complete medium (RPMI 1640 supplemented with 10% FCS, 1% L-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin; all obtained from Sigma, St. Louis, MO) at a concentration of 2 x 106 cells/ml and were cultured in the presence or the absence of a neutralizing anti-IL-17 Ab (at a final concentration of 1, 10, or 100 ng/ml) or a nonrelevant control Ab (anti-IL-4 Ab, 1 µg/ml; both purchased from R&D Systems, Minneapolis, MN) for 18 h. PBMC were also isolated by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway) from 10-ml heparinized blood samples. To examine whether IL-17 enhances IL-8 secretion in gastric epithelial cells, MKN 28 cells (gift from Dr. Zarrilli, University of Naples, Naples, Italy) were resuspended in DMEM supplemented with 10% FBS, 2 mmol glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin (all obtained from Sigma) at a concentration of 3 x 106 cells/ml and were cultured until they reached confluence. After that, MKN 28 cells were stimulated with or without graded doses of recombinant human IL-17 (rhIL-17; final concentrations, 1, 10, and 100 ng/ml; R&D Systems) for 6, 12, 18, and 24 h.
Gastric tissue homogenate preparation for RNA analysis
Gastric biopsy specimens were used for RNA and protein analysis of freshly obtained whole tissue. Mucosal samples were separately placed in sterile tubes containing 12 ml of cold guanidine thiocyanate buffer (for RNA extraction) or 0.5 ml of lysis buffer (for protein extraction). The latter contained 0.0625 mol/L Tris (pH 6.8), 2% SDS, 3% 2-ME, 10% glycerol, 100 mmol/L sodium fluoride, 10 µg/L aprotinin, 10 µg/ml leupeptin, and 1 mmol/L PMSF (all from Sigma). Tissue samples were homogenized using a tissue homogenizer (model no. D-7801, Ystral, Dottingen, Germany).
RNA and cDNA preparations
Total RNA was extracted from mucosal samples according to the method of Chomczynski and Sacchi (21). The sample obtained was quantitated by absorbance at 260 nm. RNA integrity was assessed by electrophoresis on a 1.5% agarose gel. cDNA was synthesized from 1 µg of total RNA using 0.2 U of murine leukemia virus reverse transcriptase (Promega, Madison, WI), 2.5 mM random hexamers (Roche, Mannheim, Germany), 1 mM dNTP (Roche), and 2 U of RNase inhibitor (Promega) in a total volume of 20 µl. The reaction was performed at 37°C for 60 min.
RT-PCR
Before examining transcripts for IL-17 and IL-17R, the sample cDNA content was normalized with a ß-actin signal. For this purpose, varying amounts of cDNA were incubated in a PCR for 19, 20, 21, 22, and 23 cycles with ß-actin-specific primers. IL-17 and IL-17R primers were assayed in all samples by incubating an equivalent amount of cDNA for 35 cycles. PCR were performed in a total volume of 50 µl in the presence of 1 U of Taq DNA polymerase (Roche), 200 mmol of dNTPs (Roche), and 25 pmol/L 5' and 3' primers. Reactions were incubated in a Robocycler thermal cycler (Stratagene, La Jolla, CA; denaturation for 1 min at 94°C, annealing for 1 min at 55°C, and extension for 1 min at 72°C).
PCR primers (Genosys, Cambridge, U.K.) were as follows: ß-actin, 5'-CGAGGCCCAGAGCAAGAGA-3' and 3'-CGTGACATTAAGGAGAAGCTGTG-5'; IL-17, 5'-GGACTACCACATGAACTCTG-3' and 3-CATATCTTGGCCAAGTGTTAC-5'; and IL-17R, 5'-GCTTCACCCTGTGGAACGAATC-3' and 3-GGAGATGCCCGTGATGATGAACC-5'.
To exclude the amplification of genomic DNA contaminating the samples, experiments were also performed using RNA as substrate for PCR assay. Ten microliters of PCR product was combined with 1 µl of loading buffer and electrophoresed on a 1.5% agarose gel (in Tris-EDTA buffer). A 123-bp ladder was used to assess sample size. The specificity of the PCR products was confirmed by specific restriction enzymes.
Southern blotting
To assess IL-17 semiquantitatively, Southern blotting analysis was performed as previously indicated (22). In preliminary experiments we established the optimal number of RT-PCR cycles for obtaining a product within the linear portion of the curve. An equivalent amount of cDNA was therefore incubated for 18 or 22 cycles with ß-actin- or IL-17-specific primers, respectively. PCR were performed in a total volume of 50 µl. The PCR products were detected by Southern blot hybridization using specific cDNA probes. The cDNA probes were DNA fragments encoding the full-length PCR product. RT-PCR products were used as probes only after each product was cloned, and its sequence verified. The level of RNA transcripts was measured by laser densitometry (NIH Image software) and expressed as arbitrary units.
Protein extraction and Western blot analysis
Total proteins were extracted from both freshly obtained mucosal samples and LPMC by using the above mentioned lysis buffer. After cell lysis, the supernatant was collected, run at 4000 x g for 40 min (4°C), and stored at -80°C until assay. Total proteins were separated on a 15% SDS-PAGE gel and electrophoretically transferred onto an Immobilon-P membrane (Amersham, Aylesbury, U.K.). IL-17 was detected using an anti-IL-17 (1/500 final dilution), capable of recognizing the carboxyl terminus of IL-17 (Santa Cruz Biotechnology, Santa Cruz, CA), followed by an HRP-conjugated goat anti-mouse IgG mAb (Santa Cruz Biotechnology; final dilution, 1/2500). Ab reaction was detected with a chemiluminescence detection kit (Amersham). To confirm the equal loading of proteins, Ponceau S staining was performed.
IL-8 ELISA
IL-8 was measured in LPMC and MKN 28 supernatants using a sensitive ELISA (R&D Systems). The minimum detectable IL-8 concentration was 5 pg/ml.
Assessment of IL-17 effects on PMN chemotaxis
Dextran-separated PMN, isolated from healthy donors, were resuspended in DMEM at a final concentration of 3 x 106 cells/ml. The chemotaxis assay was performed in a 48-well microchemotaxis chamber (Corning-Costar, Cambridge, MA) as previously described (23). Briefly, the bottom wells of the chamber were filled with 25 µl of fluid containing either rhIL-8 (at a final concentration of 1 ng/ml), the control solution (DMEM with 1% BSA), the conditioned medium (IL-17-stimulated MKN 28 cell culture supernatant), or rIL-17 (100 ng/ml). A filter with pore size of 3 mm was placed on the bottom wells, and 50 µl of neutrophil suspension were pipetted into upper wells as triplicate samples. The chamber was incubated in humidified air with 5% CO2 at 37°C for 30 min. PMN that completely migrated through the filter were counted in five random high power fields (HPF). The chemotactic response was defined as the mean number of migrating PMN per HPF. To ascertain whether the chemotactic effects of IL-17 were dependent by IL-8, we performed a parallel chemotaxis assay in which either a neutralizing anti-hIL-8 (10 ng/ml) or IL-17 Ab (10 ng/ml) was added to the conditioned medium 15 min before experiment.
Statistical calculations
Differences between groups were compared with Students t test and Mann-Whitney U test. IL-17 blots were scanned using laser densitometry analysis (NIH Image software). The resulting arbitrary units were correlated with gastritis and Hp density scores by means of Pearsons correlation test. p < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Transcripts for IL-17 were detected in the gastric tissue
homogenates from both Hp-infected patients and
uninfected subjects. When IL-17 RNA transcripts were analyzed by
semiquantitative RT-PCR, an increased accumulation was seen in whole
mucosal tissue from patients with Hp infection compared with
uninfected subjects (Fig. 1
).
Consistently, a more pronounced accumulation of IL-17 RNA transcripts
was detected in LPMC isolated from the gastric mucosa of patients with
Hp compared with normal controls (Fig. 1
). IL-17 was barely
detectable in PBMC, with no difference between Hp patients
and controls. Transcripts for IL-17R were present in both whole mucosal
gastric and LPMC samples (Fig. 2
).
|
|
20 kDa (Fig. 3
|
|
The demonstration that gastric LPMC contain transcripts for IL-17R
suggests that these cells are potential targets of IL-17 in vivo.
Evidence has accumulated to indicate that both epithelial cells and
macrophage-like cells infiltrating the Hp-colonized mucosa
produce IL-8 (3). In addition, it has been reported that
IL-17 is capable of inducing IL-8 in both epithelial cells and
macrophages in other systems (14, 15) We therefore
examined the ability of the locally produced IL-17 to modulate IL-8
production in gastric LPMC. For this purpose, LPMC were isolated from
the stomach of patients with Hp infection and incubated with
graded doses of a neutralizing anti-IL-17 Ab. After 18 h of
culture, the amount of IL-8 released in the LPMC culture supernatants
was measured by ELISA. As shown in Fig. 5
the addition of an anti-IL-17 Ab to the LPMC cultures
down-regulated IL-8 secretion. The amounts of IL-8 released by LPMC
cultured in the presence of 1, 10, and 100 ng/ml anti-IL-17 Ab were
21, 50, and 59% lower than those measured in unstimulated LPMC culture
supernatants (p < 0.01, by Students paired,
two-way t test; n = 6; 1, 10, and 100 ng/ml
vs basal secretion; Fig. 5
). The effect of anti-IL-17 appeared to
be specific. No inhibition of IL-8 production was seen when LPMC were
cultured in the presence of control Ab. In addition, LPMC viability was
not affected by anti-IL-17 treatment.
|
To further substantiate the role of IL-17 in the induction of IL-8
in gastric mucosa, we tested the effect of rhIL-17 on secretion of IL-8
by MKN 28 cells, a gastric epithelial cell line. We first showed that
MKN 28 cells express transcripts for IL-17R. This is consistent with
the demonstration that IL-17R is expressed in several cell types, and
epithelial cells are potential targets of IL-17 (12, 13, 14, 15).
Indeed, stimulation of MKN 28 cells with rhIL-17 was followed by an
increase in IL-8 secretion (Fig. 6
). This
effect was dose dependent. The addition of 1, 10, and 100 ng/ml IL-17
increased IL-8 secretion of 44, 138, and 280%
(p < 0.01, n = 6; 10 and 100
ng/ml vs basal secretion; p = NS, n =
6, 1 ng/ml vs basal secretion; by Students paired, two-way
t test; Fig. 6
). The enhancing effect of IL-17 on IL-8 was
neutralized by coincubation with anti-IL-17, but not control,
Ab.
|
|
| Discussion |
|---|
|
|
|---|
IL-17 is a recently described cytokine that is capable of modulating the expression of various genes in fibroblasts, macrophages, and epithelial and endothelial cells and is implicated in the pathogenesis of human inflammatory diseases (10, 14, 24, 25, 26). Of the large number of cell types analyzed for IL-17 expression, it is the T lymphocyte that appears to be the only producer of IL-17 (10, 11). In particular, IL-17 is produced by CD45RO+, but not CD45RA+, T cells (27). We report that LPMC isolated from the human gastric mucosa express IL-17 at both RNA and protein levels. This appears to be consistent with the demonstration that the vast majority of lymphocytes infiltrating the gastrointestinal mucosa bear the phenotype of Ag-experienced memory T cells (20, 23, 24, 25, 26, 27, 28, 29, 30). When RNA transcripts for IL-17 were analyzed by a semiquantitative RT-PCR, an increased accumulation was found in both mucosal tissue and LPMC samples from Hp-infected patients compared with that in uninfected subjects. Similarly, the amount of IL-17 protein, as determined by Western blotting, was increased in the mucosa of Hp-infected patients. In addition, Hp eradication resulted in a down-regulation of IL-17 production. As no difference in terms of IL-17 expression was seen in blood lymphocytes isolated from patients with Hp and controls, it is highly likely that the mucosal microenvironment, determined by the bacteria infection, influences IL-17 expression. Among T cells, the activated Th1/Th0 cell subset is the major source of IL-17 (11). Consistently, IL-17 has been found to be increased in Th1-mediated diseases (14, 24, 25). Our data are thus in line with these studies, given that it is known that the local immune inflammatory response during Hp infection is predominantly Th1 in type (16, 17, 18).
The greater expression of IL-17 seen in Hp-positive biopsies compared with that found in Hp-negative samples may depend on the more pronounced infiltration of memory T cells in the Hp-colonized mucosa. This is also consistent with our finding of a positive correlation between IL-17 levels and gastritis score in the Hp-positive group. Analysis of IL-17 in other forms of gastritis by comparison with Hp-associated gastritis would be useful to establish whether up-regulation of IL-17 specifically occurs during Hp infection or simply reflects a general phenomenon of all forms of gastritis. Unfortunately, in the geographical area where we work, the high prevalence of Hp infection in the population undergoing esophagogastroduodenoscopy makes it extremely difficult to sample biopsies from Hp-negative gastritis. The fact that in the Hp-positive patients matched for the level of gastritis IL-17 correlates with the density of Hp infection, however, suggests a possible direct effect of the infection on IL-17 induction.
The Hp-associated gastritis is characterized by an
infiltrate constituted by both acute and chronic inflammatory cells.
The migration of PMN into the mucosa is thought to be dependent on the
expression of chemokines (1, 2). Once they arrive in the
mucosa, these cells become active and release enzymes that are
potentially capable of causing epithelial damage (1).
Several lines of evidence indicate that locally induced IL-8 plays a
major role in the recruitment of PMN (3, 4, 5, 7). Although
Hp by itself or its product has been reported to be a potent
inducer of IL-8 synthesis, it is well known that cytokines released by
activated macrophages and T cells may modulate IL-8 expression in both
mononuclear and epithelial cells (9). In this context, an
interesting finding of the present study is the demonstration that in
the gastric mucosa, IL-17 has regulatory activity on IL-8 synthesis.
Neutralization of IL-17 resulted in a significant inhibition of IL-8
production in gastric LPMC, and the addition of rhIL-17 to the cultures
of MKN 28 cells increased IL-8 secretion. These data thus support
previous studies indicating the ability of IL-17 to induce IL-8
expression in other systems (15). Although the mechanisms
through which IL-17 enhances IL-8 have not been extensively
investigated, it is known that IL-17 can activate transcription
factors, such as NF-
B and mitogen-activated protein kinases
(31), that are capable of initiating IL-8 expression
(12, 32). We moreover showed that through selective
induction of IL-8, IL-17 enhanced the in vitro chemotaxis of PMN,
suggesting a possible role for this cytokine in maintaining and
expanding the acute inflammatory component during Hp
infection.
In addition to its ability to enhance IL-8 production, IL-17 might
modulate the expression of other molecules relevant to the
pathophysiology of peptic disease. Indeed, IL-17 can increase the
synthesis of both proinflammatory cytokines, such as IL-1ß, IL-6, and
TNF-
, and stromelysin-1, a matrix metalloproteinase (13, 31, 33). This enzyme is capable of causing mucosal degradation and
has been associated with gastrointestinal ulceration
(33).
In conclusion, we report an increased expression of T cell-derived IL-17 in the gastric mucosa of patients with Hp infection, suggesting that this cytokine may play an important role in the inflammatory response to the Hp colonization and ultimately influence the outcome of the Hp-associated disease.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Francesco Luzza, Dipartimento di Medicina Sperimentale e Clinica, Università di Catanzaro Magna Graecia, Via T Campanella 115, 88100 Catanzaro, Italy. ![]()
3 Abbreviations used in this paper: Hp, Helicobacter pylori; rh, recombinant human; PMN, polymorphonuclear leukocytes; LPMC, lamina propria mononuclear cells; HPF, high power field. ![]()
Received for publication June 12, 2000. Accepted for publication August 2, 2000.
| References |
|---|
|
|
|---|
and interferon
synergistically induce interleukin 8 production in a human gastric cancer line through acting concurrently on AP-1 and NF-
B-like binding sites of the interleukin 8 gene. J. Biol. Chem. 267:22506.
, by human macrophages. J. Immunol. 160:3513.
and interleukin-4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36:341.
B. J. Biol. Chem. 273:27467.This article has been cited by other articles:
![]() |
S. Shahrara, S. R. Pickens, A. Dorfleutner, and R. M. Pope IL-17 Induces Monocyte Migration in Rheumatoid Arthritis J. Immunol., March 15, 2009; 182(6): 3884 - 3891. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Webb, A. Johnson, M. Fortunato, A. Platt, T. Crabbe, M. I. Christie, G. F. Watt, S. G. Ward, and L. A. Jopling Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists J. Leukoc. Biol., October 1, 2008; 84(4): 1202 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J Blaser, Y Chen, and J Reibman Authors' response Gut, August 1, 2008; 57(8): 1179 - 1179. [Full Text] [PDF] |
||||
![]() |
K. Yamauchi, I.-J. Choi, H. Lu, H. Ogiwara, D. Y. Graham, and Y. Yamaoka Regulation of IL-18 in Helicobacter pylori Infection J. Immunol., January 15, 2008; 180(2): 1207 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Niess, F. Leithauser, G. Adler, and J. Reimann Commensal Gut Flora Drives the Expansion of Proinflammatory CD4 T Cells in the Colonic Lamina Propria under Normal and Inflammatory Conditions J. Immunol., January 1, 2008; 180(1): 559 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maitra, F. Shen, W. Hanel, K. Mossman, J. Tocker, D. Swart, and S. L. Gaffen Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression PNAS, May 1, 2007; 104(18): 7506 - 7511. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Mathur, H.-C. Chang, D. G. Zisoulis, R. Kapur, M. L. Belladonna, G. S. Kansas, and M. H. Kaplan T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype Blood, September 1, 2006; 108(5): 1595 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. K. Liu, X. Lin, and S. L. Gaffen Crucial Role for Nuclear Factor of Activated T Cells in T Cell Receptor-mediated Regulation of Human Interleukin-17 J. Biol. Chem., December 10, 2004; 279(50): 52762 - 52771. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sebkova, A. Pellicano, G. Monteleone, B. Grazioli, G. Guarnieri, M. Imeneo, F. Pallone, and F. Luzza Extracellular Signal-Regulated Protein Kinase Mediates Interleukin 17 (IL-17)-Induced IL-8 Secretion in Helicobacter pylori-Infected Human Gastric Epithelial Cells Infect. Immun., September 1, 2004; 72(9): 5019 - 5026. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kranzer, A. Eckhardt, M. Aigner, G. Knoll, L. Deml, C. Speth, N. Lehn, M. Rehli, and W. Schneider-Brachert Induction of Maturation and Cytokine Release of Human Dendritic Cells by Helicobacter pylori Infect. Immun., August 1, 2004; 72(8): 4416 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ruddy, F. Shen, J. B. Smith, A. Sharma, and S. L. Gaffen Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment J. Leukoc. Biol., July 1, 2004; 76(1): 135 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Fujino, A Andoh, S Bamba, A Ogawa, K Hata, Y Araki, T Bamba, and Y Fujiyama Increased expression of interleukin 17 in inflammatory bowel disease Gut, January 1, 2003; 52(1): 65 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Maertzdorf, A. D. M. E. Osterhaus, and G. M. G. M. Verjans IL-17 Expression in Human Herpetic Stromal Keratitis: Modulatory Effects on Chemokine Production by Corneal Fibroblasts J. Immunol., November 15, 2002; 169(10): 5897 - 5903. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aggarwal and A. L. Gurney IL-17: prototype member of an emerging cytokine family J. Leukoc. Biol., January 1, 2002; 71(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Cox, C. L. Clayton, T. Tomita, D. M. Wallace, P. A. Robinson, and J. E. Crabtree cDNA Array Analysis of cag Pathogenicity Island-Associated Helicobacter pylori Epithelial Cell Response Genes Infect. Immun., November 1, 2001; 69(11): 6970 - 6980. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Akkoyunlu, S. E. Malawista, J. Anguita, and E. Fikrig Exploitation of Interleukin-8-Induced Neutrophil Chemotaxis by the Agent of Human Granulocytic Ehrlichiosis Infect. Immun., September 1, 2001; 69(9): 5577 - 5588. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |